An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101

Cancer Discovery

Volumn 5, Issue 10, 2015, Pages 1049-1057

  Doebele, Robert C ^a   Davis, Lara E ^b   Vaishnavi, Aria ^a   Le, Anh T ^a   Estrada Bernal, Adriana ^a   Keysar, Stephen ^a   Jimeno, Antonio ^a   Varella Garcia, Marileila ^a   Aisner, Dara L ^a   Li, Yali ^c   Stephens, Philip J ^c   Morosini, Deborah ^c   Tuch, Brian B ^d   Fernandes, Michele ^d   Nanda, Nisha ^d   Low, Jennifer A ^d  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c FOUNDATION MEDICINE   (United States)

^d Loxo Oncology Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; IFOSFAMIDE; LAMIN A; LAMIN C; SORAFENIB; TROPOMYOSIN RELATED KINASE INHIBITOR; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; ARRY-470; ONCOGENE PROTEIN TRK; ONCOPROTEIN; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; DNA SEQUENCE; DRUG DOSE ESCALATION; DRUG SAFETY; FUSION GENE; GENE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MOUSE; MULTICENTER STUDY; NEXT GENERATION SEQUENCING; NONHUMAN; NTRK1 GENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOFT TISSUE SARCOMA; ADULT; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL TRANSFORMATION; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; FEMALE; GENETICS; SARCOMA; TREATMENT OUTCOME; TUMOR CELL LINE; X-RAY COMPUTED TOMOGRAPHY;

ADULT; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LAMIN TYPE A; NEOPLASM STAGING; ONCOGENE PROTEINS; ONCOGENE PROTEINS, FUSION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIMIDINES; SARCOMA; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84943338865     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0443     Document Type: Article

References (32)

1. Nakagawara A. Trk receptor tyrosine kinases: a bridge between cancer and neural development. Cancer Lett 2001;169:107-14.
2. Pulciani S, Santos E, Lauver AV, Long LK, Aaronson SA, Barbacid M. Oncogenes in solid human tumours. Nature 1982;300:539-42.
3. Martin-Zanca D, Hughes SH, Barbacid M. A human oncogene formed by the fusion of truncated tropomyosin and protein tyrosine kinase sequences. Nature 1986;319:743-8.
4. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963-71.
5. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-97.
6. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015;5:25-34.
7. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013;19:1469-72.
8. Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 2013;19:4040-5.
9. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumors and spitzoid melanomas. Nat Commun 2014;5:3116.
10. Taipale M, Krykbaeva I, Whitesell L, Santagata S, Zhang J, Liu Q, et al. Chaperones as thermodynamic sensors of drug-target interactions reveal kinase inhibitor specificities in living cells. Nat Biotech 2013;31:630-7.
11. Smith MA, Hall R, Fisher K, Haake SM, Khalil F, Schabath MB, et al. Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays. Sci Signal 2015;8:ra4.
12. Stephens RM, Loeb DM, Copeland TD, Pawson T, Greene LA, Kaplan DR. Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron 1994;12:691-705.
13. Kaplan DR, Martin-Zanca D, Parada LF. Tyrosine phosphorylation and tyrosine kinase activity of the trk proto-oncogene product induced by NGF. Nature 1991;350:158-60.
14. Dolle JP, Rezvan A, Allen FD, Lazarovici P, Lelkes PI. Nerve growth factor-induced migration of endothelial cells. J Pharmacol Exp Ther 2005;315:1220-7.
15. Klijn C, Durinck S, Stawiski EW, Haverty PM, Jiang Z, Liu H, et al. A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 2015;33:306-12.
16. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014;5:4846.
17. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, et al. The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 2013;45:1141-9.
18. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005;353:701-11.
19. Linch M, Miah AB, Thway K, Judson IR, Benson C. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol 2014;11:187-202.
20. Lorigan P, Verweij J, Papai Z, Rodenhuis S, Le Cesne A, Leahy MG, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007;25:3144-50.
21. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-45.
22. Sleijfer S, Ouali M, van Glabbeke M, Krarup-Hansen A, Rodenhuis S, Le Cesne A, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTCSTBSG). Eur J Cancer 2010;46:72-83.
23. Sleijfer S, Seynaeve C, Verweij J. Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005;10:833-41.
24. Rutkowski P, Debiec-Rychter M, Nowecki Z, Michej W, Symonides M, Ptaszynski K, et al. Treatment of advanced dermatofibrosarcoma protuberans with imatinib mesylate with or without surgical resection. J Eur Acad Dermatol Venereol 2011;25:264-70.
25. Rafee S, Elamin YY, Joyce E, Toner M, Flavin R, McDermott R, et al. Neoadjuvant crizotinib in advanced inflammatory myofibroblastic tumour with ALK gene rearrangement. Tumori 2015;101:e35-9.
26. Lovly CM, Gupta A, Lipson D, Otto G, Brennan T, Chung CT, et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014;4:889-95.
27. Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med 2010;363:1727-33.
28. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res 2012;22:2109-19.
29. Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet 2013;22:795-803.
30. Morosini D, Chmielecki J, Goldberg M, Ross JS, Stephens PJ, Miller VA, et al. Comprehensive genomic profiling of sarcomas from 267 adolescents and young adults to reveal a spectrum of targetable genomic alterations. J Clin Oncol 2015;33:Suppl; abstr 11020.
31. Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, et al. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One 2013;8:e82236.
32. Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol 2013;7:776-90.